Accrediting Body
BMJ Learning - British Medical Learning
Expected length
60 minutes
Award
1 credit
Subscription
Register (90)
Through interactive case histories, learn how to advise men who are worried about prostate cancer, and the treatment options available to men diagnosed with clinically localised cancer. With multimedia video.
After completing this module, you should know:
- How to advise men who are worried about prostate cancer
- What information you should give them
- The treatment options available to men diagnosed with clinically localised cancer.
Category | Value |
---|---|
Credit type | Credit |
Registration with provider required | Yes |
Certificate available | Yes |
Author(s) | BMJ Learning with the NHS prostate cancer management programme |
Multi session | No |
Intended audience(s) | General Practitioner |
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
CDK 4/6 inhibitors in metastatic breast cancer
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Transplantation
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
+ 2 more
Related Content
Managing the side effects of treatment for prostate cancer
- Accrediting body
- BMJ Learning - British Medical Learning
- Credits available
- 1
- Registration required
- true
- Subscription fee
- 90
Guidance update: latest NICE guidelines on prostate cancer
- Accrediting body
- MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- 1
- Registration required
- true
- Subscription fee
- 154.8
Prostate cancer: clinical review
- Accrediting body
- MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- 1
- Registration required
- true
- Subscription fee
- 0
Prostate cancer survivorship and long term care - in association with Prostate Cancer UK
- Accrediting body
- Union of European Medical Specialists (via European Accreditation Council for CME)
- Credits available
- 1
- Registration required
- true
- Subscription fee
- 90
Prostate cancer: understanding the patient pathway and treatment options - in association with Prostate Cancer UK
- Accrediting body
- Union of European Medical Specialists (via European Accreditation Council for CME)
- Credits available
- 1
- Registration required
- true
- Subscription fee
- 90
Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.
This study aims to evaluate the effectiveness, safety and cost of abiraterone acetate (AA) in patients with mCRPC.
Added 6 months ago
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
In this key paper evaluation, the authors discuss the rational, trial design and results of the LATITUDE trial. Furthermore, the past and current standard of care of metastatic castrate-naïve prostate cancer (mCNPC)...
Added 6 months ago
Abiraterone acetate in the treatment of prostate cancer.
Herein, the in-detail pharmacological profile of AA, including androgen signaling, mechanism of action of AA, mechanism of AA resistance, pharmacokinetics, latest clinical findings...
Added 6 months ago
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic...
Added 7 months ago
A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.
The purpose of this study was to determine the efficacy of 8 weeks of degarelix for prostate downsizing before interstitial brachytherapy. We also report associated toxicity and the time course of endocrine recovery over the following 12 months.
Added 11 months ago
Darolutamide + ADT extends metastasis-free survival in non-metastatic castration-resistant prostate cancer. Bayer HealthCare
Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant...
Added 2 days ago
Opdivo + Yervoy success in CheckMate 650 trial for prostate cancer. -BMS
Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer...
Added 3 days ago
Keytruda and Lynparza early findings for treatment of prostate cancer.- Merck Inc.
Merck Inc., announced the presentation of interim data from the Phase 1b/II KEYNOTE-365 umbrella trial investigating Keytruda, Merck’s anti-PD-1 therapy,...
Added 4 days ago
Phase III ARCHES trial of Xtandi meets primary endpoint in metastatic prostate cancer.- Pfizer Inc. and Astellas
Pfizer Inc. and Astellas Pharma announced results from the Phase III ARCHES trial of Xtandi (enzalutamide) in men with metastatic...
Added 6 days ago
Successful phase III TITIAN trial of Erleada for metastatic castration-sensitive prostate cancer. Janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the unblinding of the Phase III TITAN study evaluating Erleada (apalutamide)...
Added 17 days ago
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
This study will investigate the efficacy of Degarelix, a Luteinizing Hormone Releasing Hormone (LHRH) antagonist, to reduce prostate volume prior to permanent seed prostate brachytherapy.
Added 11 months ago
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
Added 1 year ago
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC)...
Added 1 year ago
Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer
Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens.
Added 1 year ago
A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)
A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1‐2 lines of chemotherapy and at least 12 weeks of abiraterone with a safety run‐in and single stage phase II expansion cohort.
Added 1 year ago
EAU Guidelines on Prostate Cancer
The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals assess the evidence-based management of prostate cancer (PCa).
Added 2 years ago
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...
Added 3 years ago
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index
NICE has not recommended the PROGENSA PCA3 assay and the Prostate Health Index for use in people having investigations for suspected prostate cancer, who have had a negative or inconclusive transrectal ultrasound prostate biopsy.
Added 3 years ago
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.